LL-37 in the Gut: Your Body's Natural Antibiotic

LL-37 and Gut Health

37 amino acids

LL-37 is the only cathelicidin antimicrobial peptide in the human body, and its expression in colonic epithelium is a primary mechanism of innate intestinal defense against bacterial pathogens.

Iimura et al., Journal of Immunology, 2005

Iimura et al., Journal of Immunology, 2005

View as image

Humans carry exactly one cathelicidin gene. That gene produces one mature peptide: LL-37, a 37-amino-acid cationic molecule that forms the backbone of antimicrobial defense across the gut, skin, and respiratory tract. In the colon, LL-37 is constitutively expressed by surface epithelial cells, where it kills adherent pathogens, preserves tight junction integrity, and accelerates wound repair.^[1] When cathelicidin production fails or falls, as it does in inflammatory bowel disease, the consequences are measurable: increased pathogen colonization, barrier breakdown, and amplified inflammation.^[2] This article covers the full scope of LL-37's role in the gastrointestinal tract, from its expression in healthy epithelium to its dysregulation in disease, and what research has revealed about its therapeutic potential. For a closer look at how LL-37 interacts with bacterial communities, see LL-37 and the Gut Microbiome: Friend or Foe to Your Bacteria?. For its specific role in barrier maintenance, see LL-37 and the Intestinal Barrier.

What Is LL-37 and Where Is It Made?

LL-37 is processed from a precursor protein called hCAP18 (human cationic antimicrobial protein 18), which is encoded by the CAMP gene. The mature 37-residue peptide adopts an alpha-helical structure in the presence of bacterial membranes, allowing it to insert into and disrupt lipid bilayers. This mechanism is shared across the cathelicidin family in other species, but humans express only one member: LL-37.^[3]

In the gastrointestinal tract, LL-37 expression follows a specific distribution pattern. Hase et al. (2002) showed that LL-37/hCAP18 is expressed by differentiated surface colonocytes in the adult colon, with minimal expression in the small intestine and none in undifferentiated crypt cells.^[4] This localization matters: surface colonocytes are the cells directly exposed to the colonic lumen, making LL-37 a first-contact defense molecule. The differentiation-dependent expression means that only mature, surface-facing epithelial cells produce LL-37, creating a targeted shield precisely where pathogen contact occurs.

Beyond colonocytes, LL-37 is also produced by neutrophils that migrate to sites of intestinal inflammation, by macrophages activated in the lamina propria, and by gastric epithelial cells in the stomach.^[5] Each of these cellular sources contributes to the total cathelicidin pool in the gut, but the constitutive epithelial expression represents the standing defense, while immune cell production ramps up during active infection or inflammation. For more on how antimicrobial peptides broadly shape microbial communities, see How Your Antimicrobial Peptides Shape Your Microbiome.

Direct Antimicrobial Defense in the Intestine

The functional proof that cathelicidin defends the gut against pathogens came from knockout studies. Iimura et al. (2005) demonstrated that mCRAMP (the mouse ortholog of LL-37) expression in the intestinal tract is largely restricted to colonic surface epithelial cells, mirroring human LL-37 distribution. Synthetic mCRAMP exhibited direct antimicrobial activity against Citrobacter rodentium, a murine pathogen that models the human enteropathogens enteropathogenic and enterohemorrhagic Escherichia coli.^[1]

When the researchers infected mCRAMP-knockout mice with C. rodentium, the cathelicidin-deficient animals showed markedly increased bacterial colonization of the colonic surface compared to wild-type mice. The bacteria penetrated deeper into the colonic mucosa in knockout animals, demonstrating that cathelicidin provides a physical antimicrobial barrier at the epithelial surface. This was the first direct evidence that endogenous cathelicidin mediates innate intestinal defense against colonization with epithelial-adherent bacterial pathogens.

The mechanism extends to the stomach. Hase et al. (2003) found that LL-37/hCAP18 was elevated in the epithelium and gastric secretions of patients infected with Helicobacter pylori. Synthetic LL-37 killed H. pylori at concentrations consistent with those found in vivo, and gastric epithelial cell lines upregulated LL-37 expression in response to H. pylori contact through a pathway involving NF-kB activation.^[5] This gastric response demonstrates that LL-37 functions as an inducible defense across the entire gastrointestinal tract, not just the colon.

Keshri et al. (2025) reviewed the broader antimicrobial mechanisms of LL-37 beyond direct membrane disruption. LL-37 also neutralizes bacterial lipopolysaccharide (LPS), preventing the endotoxin-driven inflammatory cascade that can cause sepsis. It disrupts bacterial biofilms, which are relevant to intestinal pathogens that form protective communities on mucosal surfaces. And it acts as a chemoattractant, recruiting neutrophils and monocytes to sites of infection to amplify the antimicrobial response.^[6] These functions position LL-37 as both a direct killer and an orchestrator of the broader immune response in the gut. For details on how antimicrobial peptides physically destroy bacterial membranes, see How Antimicrobial Peptides Kill Bacteria: Pore Formation Explained.

Protecting the Intestinal Barrier

Killing pathogens is only part of what LL-37 does in the gut. Otte et al. (2009) performed the most detailed characterization of LL-37's effects on intestinal epithelial barrier integrity. Using colonic HT-29 and Caco-2 cell models, they demonstrated three distinct protective mechanisms.^[7]

First, LL-37 stimulated intestinal epithelial cell migration. Direct application of LL-37 promoted migration in Caco-2 cells expressing the proposed LL-37 receptor P2X7. Indirectly, LL-37 enhanced intestinal epithelial cell migration through the release of growth factors from subepithelial fibroblasts, suggesting a paracrine signaling loop where LL-37 acts on underlying stromal cells that in turn support epithelial repair.

Second, LL-37 induced the expression of protective mucins in intestinal epithelial cells. Mucins form the gel-like layer that separates the epithelium from the luminal contents, and increased mucin production strengthens this physical barrier against both pathogens and digestive enzymes.

Third, LL-37 blocked TRAIL-induced apoptosis in intestinal epithelial cells. TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a pro-apoptotic signal that is elevated during intestinal inflammation. By suppressing TRAIL-mediated cell death, LL-37 preserves epithelial cell numbers during inflammatory episodes, preventing the barrier gaps that allow bacterial translocation.

Wu et al. (2010) placed these findings in a broader therapeutic context, reviewing cathelicidin's potential applications for gastrointestinal disorders. They noted that cathelicidins promote wound healing through the stimulation of vascular endothelial growth factor (VEGF) production and angiogenesis, which are essential for mucosal repair after injury. In addition, cathelicidins modulate the inflammatory cytokine profile, reducing pro-inflammatory IL-1beta and TNF-alpha while preserving anti-inflammatory IL-10.^[8] This combination of wound healing promotion and inflammation modulation makes cathelicidin a candidate for treating conditions characterized by chronic mucosal injury.

LL-37 in Inflammatory Bowel Disease

The relationship between LL-37 and inflammatory bowel disease (IBD) has been investigated from multiple angles: expression patterns in diseased tissue, circulating levels as biomarkers, and therapeutic effects in animal models.

Expression in Diseased Tissue

Kusaka et al. (2018) conducted the most thorough examination of LL-37 expression patterns in IBD tissue. They found that LL-37 mRNA was elevated in the inflamed mucosa of ulcerative colitis (UC) patients. However, the pattern differed in Crohn's disease (CD): LL-37 expression was not measurably changed in either inflamed or non-inflamed colonic or ileal mucosa of CD patients.^[9]

This differential expression is significant. Ulcerative colitis is confined to the colon, where LL-37 is constitutively expressed. The upregulation in UC mucosa likely represents an amplified defensive response to the inflammatory environment. Crohn's disease often affects the ileum, where LL-37 expression is normally minimal. The failure to upregulate LL-37 in Crohn's mucosa may represent a deficiency in innate defense that contributes to pathogen persistence and chronic inflammation.

Kusaka et al. also investigated the regulatory mechanisms in human colonic subepithelial myofibroblasts (SEMFs), finding that LL-37 induction in these stromal cells was regulated by inflammatory cytokines, particularly IL-1beta and TNF-alpha. This reveals a feedback loop: inflammation triggers LL-37 production in stromal cells, and LL-37 in turn modulates inflammation, creating a regulatory circuit that can either resolve or perpetuate the inflammatory state depending on context.

Circulating Cathelicidin as a Biomarker

Tran et al. (2017) measured serum cathelicidin levels in two independent cohorts of IBD patients at the University of California, Los Angeles and the Academic Medical Center Amsterdam. Their findings established cathelicidin as a functional biomarker. Serum cathelicidin levels correlated inversely with mucosal disease activity in UC patients, meaning that lower circulating LL-37 was associated with more active mucosal inflammation.^[10]

In Crohn's disease, serum cathelicidin levels predicted the risk of intestinal stricture, a serious complication involving fibrous narrowing of the intestinal lumen. Co-evaluation of LL-37 and C-reactive protein (CRP) improved the accuracy of disease activity assessment in UC beyond either marker alone. And cathelicidin levels predicted future clinical activity in IBD patients, suggesting that LL-37 reflects underlying disease trajectories rather than just current inflammation.

Sun et al. (2016) reviewed the dual nature of LL-37 in IBD. While cathelicidin is protective through its antimicrobial and barrier-repair functions, excessive LL-37 can also promote inflammation by activating the NLRP3 inflammasome and stimulating pro-inflammatory cytokine release from macrophages. This dual role complicates therapeutic targeting: the goal would be to restore cathelicidin function without triggering its pro-inflammatory potential.^[11]

Animal Model Evidence

Tai et al. (2007) provided the most direct experimental evidence for cathelicidin's protective role in colitis. Using the dextran sulfate sodium (DSS) mouse model of ulcerative colitis, they demonstrated that intrarectal administration of mCRAMP ameliorated DSS-induced colitis. The cathelicidin-treated mice showed reduced colonic inflammation, preserved mucosal architecture, and decreased bacterial counts in fecal samples.^[12]

Critically, the reverse experiment confirmed the finding: mice with systemic cathelicidin deficiency (mCRAMP knockouts) developed more severe colitis than wild-type animals when exposed to DSS. The exacerbated colitis in knockout mice was accompanied by increased numbers of fecal microflora, confirming that cathelicidin normally restrains bacterial proliferation in the colon and that this restraint is protective against inflammatory challenge.

The combination of therapeutic benefit (exogenous cathelicidin reduces colitis) and loss-of-function harm (cathelicidin deficiency worsens colitis) establishes a causal role rather than mere association. This bidirectional evidence has been cited across subsequent reviews as one of the strongest arguments for cathelicidin-based therapeutic development in IBD.

What Regulates LL-37 in the Gut?

Vitamin D

The CAMP gene that encodes LL-37 contains a vitamin D response element (VDRE) in its promoter region, making LL-37 expression directly responsive to active vitamin D (1,25-dihydroxyvitamin D3). This regulatory relationship has clinical implications for gut health.

Gubatan et al. (2020) conducted the most comprehensive study linking vitamin D, cathelicidin, and ulcerative colitis outcomes. They found that vitamin D induced cathelicidin expression in human colonic epithelial cells in a dose-dependent manner. In UC patients, higher serum cathelicidin levels were associated with histologic mucosal healing, the most stringent measure of disease remission.^[13]

When they administered intrarectal human cathelicidin to mice with DSS-induced colitis, the treatment reduced colonic inflammation and improved mucosal histology. The study linked these observations into a pathway: vitamin D drives cathelicidin production in colonic epithelium, and cathelicidin mediates a significant portion of vitamin D's protective effect in UC. This provides a molecular explanation for the repeatedly observed association between vitamin D deficiency and poor IBD outcomes: without adequate vitamin D, the colonic epithelium cannot produce sufficient LL-37 to maintain barrier function and pathogen control.

Short-Chain Fatty Acids

Schauber et al. (2003) discovered that short-chain fatty acids (SCFAs), the primary metabolites produced by colonic bacterial fermentation of dietary fiber, regulate LL-37 expression in colonocytes. Butyrate, isobutyrate, and propionate all increased LL-37 mRNA and protein levels in colonocyte cell lines.^[14]

The regulation occurred through signaling pathways distinct from those governing cell differentiation. Inhibition of the MEK kinase enhanced butyrate-induced alkaline phosphatase activity (a marker of differentiation) while blocking LL-37 expression. Conversely, inhibition of p38/MAP kinase blocked differentiation without affecting LL-37 expression. This separation means that SCFA-driven LL-37 production is not simply a byproduct of cell maturation but an independently regulated response.

The SCFA-LL-37 connection creates a cooperative loop between the microbiome and innate defense. Beneficial bacteria produce butyrate from dietary fiber. Butyrate stimulates colonocyte LL-37 production. LL-37 suppresses pathogenic bacteria that would compete with beneficial butyrate producers. This positive feedback loop reinforces a healthy microbial community and may explain why high-fiber diets are associated with improved colonic health across multiple disease endpoints. For more on how gut peptide signaling networks operate, see Gut Peptide Hormones: The Digestive System's Signaling Network.

Cell Differentiation

Hase et al. (2002) established that LL-37 expression is tightly coupled to colonocyte differentiation. Undifferentiated cells in the colonic crypt produce little to no LL-37. As cells migrate upward from the crypt toward the surface and differentiate, LL-37 expression increases dramatically. This differentiation dependence was confirmed using sodium butyrate-induced differentiation of HT-29 and Caco-2 cell lines, where LL-37 expression tracked with differentiation markers.^[4]

The clinical significance is that conditions which impair colonocyte differentiation, including chronic inflammation, radiation injury, and certain medications, would be expected to reduce LL-37 production as a secondary consequence. This creates a vulnerability: the situations where LL-37 is most needed (active mucosal injury) are precisely when its production is most compromised.

The interplay between these three regulatory inputs creates a complex picture. Vitamin D status, dietary fiber intake (which drives SCFA production), and epithelial cell health all independently influence how much LL-37 the colon produces. A patient with vitamin D deficiency, a low-fiber diet, and inflamed mucosa would face compounding reductions in cathelicidin production from all three axes simultaneously. Conversely, optimizing vitamin D status and fiber intake could theoretically support LL-37 production even in the context of mild epithelial injury, though this hypothesis has not been tested in a clinical intervention study.

LL-37 and Colorectal Cancer

Porter et al. (2021) examined cathelicidin expression in colorectal cancer tissue and found that LL-37 expression intensity was associated with tumor progression. Higher cathelicidin expression in the colonic epithelium correlated with the presence of CD8+ T cell infiltrate in the tumor microenvironment.^[15]

Previous genetic knockout studies had shown that cathelicidin-deficient mice developed increased numbers and sizes of colorectal tumors in chemical carcinogenesis models. Porter et al. extended this to human tissue, finding that the relationship between cathelicidin and cancer depends on context. In early-stage tumors, cathelicidin expression was associated with favorable immune infiltration patterns. In advanced tumors, the relationship was more complex, with cathelicidin potentially contributing to the inflammatory microenvironment that sustains tumor growth.

This dual role mirrors the pattern seen in IBD: cathelicidin is protective under normal conditions and in early disease but can contribute to pathology when chronically elevated in the wrong context. The CD8+ T cell association is particularly relevant because these cytotoxic lymphocytes are the primary immune cells responsible for killing cancer cells. Cathelicidin's ability to recruit and activate these cells suggests that LL-37 functions as a bridge between innate and adaptive immunity in the gut.

The cancer connection also underscores the broader theme of cathelicidin as an immune sentinel rather than a simple antibiotic. LL-37 does not just kill microbes; it shapes the immune landscape of the tissue in which it is expressed. In healthy tissue, this immune shaping maintains homeostasis. In the tumor microenvironment, it influences whether the immune system mounts an effective anti-tumor response or is co-opted into supporting tumor growth. Understanding this context-dependent behavior is essential for any therapeutic application of cathelicidin in the GI tract.

Limitations of Current Research

Most direct evidence for cathelicidin function in the gut comes from mouse studies using mCRAMP, not human LL-37. While mCRAMP is functionally analogous, it is not identical: the two peptides share structural features but differ in sequence, and results from mCRAMP knockout mice may not translate perfectly to human cathelicidin deficiency.

The human data is primarily observational. Correlations between serum cathelicidin levels and IBD outcomes do not establish causation, and the UC tissue expression data from Kusaka et al. cannot determine whether LL-37 upregulation is a protective response or a pathological contributor to inflammation.

No human clinical trial has tested exogenous LL-37 as a therapeutic for any gastrointestinal condition. The mouse colitis data from Tai et al. and Gubatan et al. used intrarectal delivery, which is a specialized route that may not be practical for chronic therapy. LL-37 is susceptible to proteolytic degradation in the gut lumen, and its cost of production remains high, both obstacles to therapeutic development.

The vitamin D-cathelicidin connection, while supported by cell culture and observational data, has not been confirmed by a randomized controlled trial demonstrating that vitamin D supplementation improves IBD outcomes specifically through increased cathelicidin production. Vitamin D has multiple downstream effects, and isolating the cathelicidin-mediated component requires studies that are not yet available.

Where the Research Stands

LL-37 is one of the most studied antimicrobial peptides in the context of intestinal health, and the evidence supports a multi-layered protective role: direct pathogen killing, barrier maintenance, wound healing promotion, and immune modulation. The animal model data showing both therapeutic benefit from exogenous cathelicidin and disease worsening from cathelicidin deficiency provides strong preclinical support for a causal protective role.

The regulatory inputs from vitamin D and short-chain fatty acids connect LL-37 production to two of the most modifiable factors in gut health: nutritional status and dietary fiber intake. These connections provide mechanistic explanations for well-established epidemiological observations about vitamin D, fiber, and intestinal disease risk.

The gap between preclinical evidence and clinical application remains wide. Translating LL-37's protective properties into a viable therapeutic requires solving delivery, stability, and dosing challenges that are common to all peptide drugs but particularly acute for a molecule that must function in the proteolytically harsh environment of the gut lumen. For context on how antimicrobial peptides broadly compare to conventional antibiotics, see Antimicrobial Peptides as Alternatives to Antibiotics.

The Bottom Line

LL-37 is the sole human cathelicidin and plays a central role in intestinal defense through direct antimicrobial action, barrier maintenance, and immune modulation. Mouse knockout studies confirm its necessity for resisting intestinal pathogens, and clinical data links circulating cathelicidin levels to IBD disease activity and prognosis. Vitamin D and short-chain fatty acids from dietary fiber both drive LL-37 production in colonocytes, connecting the peptide to modifiable aspects of gut health. Clinical translation remains pending.

Frequently Asked Questions

What does LL-37 do in the gut?

LL-37 is an antimicrobial peptide produced by colonic epithelial cells that kills intestinal pathogens, maintains the epithelial barrier, and promotes wound healing. Iimura et al. (2005) showed that mice lacking cathelicidin had increased pathogen colonization of the colon. Otte et al. (2009) demonstrated that LL-37 stimulates epithelial cell migration, induces protective mucin expression, and blocks programmed cell death in intestinal cells.

Is LL-37 related to vitamin D?

LL-37 expression is directly regulated by vitamin D. The CAMP gene contains a vitamin D response element, and active vitamin D (1,25-dihydroxyvitamin D3) increases LL-37 production in colonic epithelial cells. Gubatan et al. (2020) found that higher cathelicidin levels were associated with mucosal healing in ulcerative colitis patients, providing a molecular link between vitamin D status and gut health.

Does LL-37 help with inflammatory bowel disease?

Research shows a complex relationship between LL-37 and IBD. Tai et al. (2007) found that intrarectal cathelicidin reduced colitis severity in mice, while cathelicidin-deficient mice developed worse colitis. Tran et al. (2017) showed that serum cathelicidin levels inversely correlated with disease activity in ulcerative colitis patients. No human clinical trial has yet tested LL-37 as an IBD treatment.

How does butyrate affect LL-37 production?

Butyrate and other short-chain fatty acids produced by gut bacteria from dietary fiber increase LL-37 expression in colonocytes. Schauber et al. (2003) found that this regulation operates through distinct signaling pathways independent of cell differentiation, involving MEK but not p38/MAP kinase pathways. This creates a feedback loop where beneficial bacteria promote the host's antimicrobial defenses.

Where is LL-37 expressed in the digestive system?

LL-37 is primarily expressed by differentiated surface epithelial cells in the colon, as demonstrated by Hase et al. (2002). Undifferentiated crypt cells produce little to no LL-37. The peptide is also found in gastric epithelial cells, where Hase et al. (2003) showed it is upregulated in response to H. pylori infection. Neutrophils and macrophages that infiltrate the gut during inflammation provide an additional source.

Can LL-37 levels predict IBD outcomes?

Tran et al. (2017) measured serum cathelicidin in two independent IBD patient cohorts and found that it correlated with mucosal disease activity in ulcerative colitis, predicted intestinal stricture risk in Crohn's disease, and indicated future clinical prognosis. Combined assessment of LL-37 and C-reactive protein improved disease activity measurement accuracy beyond either marker alone.